Mifepristone

SKU: orb1309767

Description

Mifepristone

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research

Key Properties

• CAS Number: 84371-65-3
• MW: 429.59
• Purity: 99.74%
• Formula: C₂₉H₃₅NO₂
• SMILES: CC#CC1(O)CCC2C3CCC4=CC(=O)CCC4=C3C(CC12C)C1=CC=C(C=C1)N(C)C
• Target: NO Synthase,Glucocorticoid Receptor,Estrogen/progestogen Receptor,Progesterone Receptor,Endogenous Metabolite,Autophagy
• Solubility: DMSO:255 mg/mL (593.59 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4.3 mg/mL (10.01 mM);Ethanol:21.5 mg/mL (50.05 mM)

Bioactivity

• Target IC50:
  CHO cells:5 nM|LNCaP cells:11.9 nM (EC50)|A549 cells:1.6 nM|K562 cells/R7:0.9 μM|HEK293 cells:0.298 nM|GR:2.6 nM|CHO cells-K1 cells:0.4 nM|T47D cells:0.045 nM|COS-7 cells:0.6 nM|MCF-7 cells:24.03 μM|SUM149PT cells:15 μM|Progesterone receptor:0.2 nM|HCC1937 cells:> 20 μM
• In Vivo:
  METHODS: To study the anti-tumor activity of Mifepristone, Mifepristone (2 mg/kg) was subcutaneously injected into a nude mouse model of cervical tumor xenotransplantation for 3 consecutive days. Then Cisplatin (3 mg/kg) was intraperitoneally injected into nude mice for 3 consecutive days. RESULTS: Tumor growth was inhibited when treated with Cisplatin alone. The combination of Cisplatin and Mifepristone led to a more significant reduction in tumor weight, reducing it by approximately 50%. METHODS: To study the anti-tumor activity of Mifepristone, Mifepristone (0.5, 1 mg/kg) was subcutaneously implanted into the subcutaneous graft tumor model established in nude mice by the SK-OV-3 ovarian cancer cell line. RESULTS: Mifepristone significantly inhibited tumor growth in a dose-dependent manner, and the effect was observed 20 days after the start of treatment. METHODS: To study the anti-tumor activity of Mifepristone, Mifepristone (50 mg/kg) was subcutaneously injected into the subcutaneous graft tumor model established in nude mice by the MKN-45 gastric cancer cell line. RESULTS: Mifepristone significantly reduced the number of lung metastases. In transplanted tumors, Mifepristone downregulated the expressions of vascular endothelial growth factor (VEGF) and microvessel density (MVD). METHODS: To study the anti-tumor activity of Mifepristone, Mifepristone (15 mg/kg) was subcutaneously injected into the subcutaneous transplanted tumor model established by the SK-N-SH neuroblastoma cell line in nude mice twice a week for a total of six times. RESULTS: Mifepristone significantly inhibited tumor growth, with an inhibition rate as high as 80%. The volume and weight of the tumor were significantly reduced after Mifepristone treatment.
• In Vitro:
  METHODS: Human MCF7 cells were treated with Mifepristone (1-100 μM) for 72 hours, and the growth inhibition of the cells was detected by the CCK-8 method. RESULTS: Mifepristone inhibited the growth of MCF7 cells (IC50=24.03 μM). METHODS: Ovarian cancer cells SK-OV-3 and OV2008 were treated with Mifepristone (5, 10, 15, 20 μM) for 3 days, and the number of surviving cells was evaluated using trypan blue staining elimination (Sigma). RESULTS: Mifepristone dose-dependently inhibited the growth of SK-OV-3 cells (IC50=6.25 μM) and OV2008 cells (IC50=6.91 μM).
• Cell Research:
  Cell growth is evaluated in various ovarian cancer cell lines that are subjected to dose-response or time course treatments. Media containing each of the doses of fresh steroids is replaced every 24 hours. Control groups of cells are treated with vehicle ethanol at a final concentration of less than 0.05%. Number of viable cells is evaluated by trypsinization and counting in a hemocytometer chamber using trypan blue dye exclusion. Experiments are conducted in media without phenol red and supplemented with charcoal extracted fetal bovine serum, or media containing unextracted serum and having phenol red. Similar results are obtained with both media preparations; therefore, after performing the growth curves, all subsequent experiments are conducted using media with unextracted serum and in the presence of phenol red. When indicated, the proliferation IC50s are calculated using software designed to study drug interaction. (Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Estrogen Receptor, EstrogenReceptor, Glucocorticoid Receptor, GlucocorticoidReceptor, NR3C3, NOSynthase, NOS, Inhibitor, inhibit, NO Synthase, Nitric oxide synthases, Mifepristone, Autophagy, C1073, C-1073, C 1073, progestogenReceptor, RU 38486, RU 486, RU486, RU-486, RU38486, RU-38486, progestogen Receptor, Progesterone Receptor, ProgesteroneReceptor, PR

Compound Identifiers

PubChem CID

4196